



392.1002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re: Applicants: Hiroyuki ABURATANI, et al.
Application No.: 10/526,741
Filing Date: November 14, 2005
For: **ANTIBODY AGAINST SECRETED N-
TERMINAL PEPTIDE OF GPC3 PRESENT IN
BLOOD OR C-TERMINAL PEPTIDE OF
GPC3**
Examiner: Peter J. Reddig
Art Unit: 1642
Confirmation No.: 4248

MAIL STOP: RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

August 7, 2009

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. § 1.97, Applicant hereby makes of record the documents listed on the accompanying PTO-1449 Form (1 page) for consideration by the Examiner in connection with the examination of the above-identified patent application. While the references are being submitted herewith, some or all of the references may not constitute prior art under the U.S. patent laws.

Pursuant to the waiver of the requirement under 37 C.F.R. §1.98(a)(2)(i) for submitting a copy of each cited U.S. Patent and U.S. Patent Application Publication for all U.S. patent

08/11/2009 MCEBREN1 00000031 500552 10526741
03 FC:1806 180.00 DA


applications filed after June 30, 2003, copies of the cited U.S. Patents are not enclosed. If it is determined that any of the listed references are not presently enclosed, the Examiner is requested to contact the undersigned so that a copy can be forwarded.

It is respectfully requested that the references cited on the accompanying Form PTO-1449 (1 sheet) be considered and made of record.

This Information Disclosure Statement is accompanied by a Request for Continued Examination and therefore is being filed under 37 C.F.R. § 1.97(b)(4), "before the mailing of a first Office action after the filing of a request for continued examination under § 1.114" and is accompanied by an authorization to charge our Deposit Account No. 50-0552 to cover the fee in the amount of \$180.00 as set forth in § 1.17(p). In the event any additional fee is due or an overpayment has been made in connection with the filing of this Information Disclosure Statement, the Commissioner is hereby authorized to charge said fee or credit said overpayment to our Deposit Account No. 50-0552.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 

Sunil Raval

Reg. No. 47,886

DAVIDSON, DAVIDSON & KAPPEL, LLC
Patents, Trademarks and Copyrights
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940